H.B. Fuller is making moves to strengthen its position in the medical adhesive technologies market. The company is announcing its plans to acquire Medifill Ltd. and has signed a provisional agreement to acquire GEM S.r.l.
Medifill Ltd. is an Irish company that specializes in the formulation and production of medical-grade cyanoacrylate adhesives. The company is known for its advanced technology and state-of-the-art clean room and manufacturing capabilities. Medifill’s products are specifically tailored for the wound closure market, with a focus on fast, safe and effective solutions.
GEM S.r.l. is an Italian manufacturer and provider of medical adhesives and application devices. The company's products are approved and certified for over 80 internal indications.
The acquisition of GEM will also establish a European headquarters for H.B. Fuller’s Medical Adhesive Technologies (MAT) business. This move is part of the company’s broader strategy to expand its medical adhesive offerings and shift its portfolio towards higher growth markets.
H.B. Fuller’s President and CEO, Celeste Mastin, highlighted the company’s focus on tissue adhesives and the potential for these products to serve as alternatives to traditional sutures and staples.
“Tissue adhesives designed for internal use offer innovative alternatives to traditional sutures, staples and embolizing agents,” said Mastin. “With the purchase of GEM, Medifill, and our previous acquisitions in this space, H.B. Fuller has now built a Medical Adhesive Technologies business founded on our expertise in cyanoacrylate chemistry, and we have extended our penetration into a global footprint.”
The company’s previous investments in the tissue adhesives market include the acquisition of Cyberbond in 2016, Tissue Seal in 2021 and Adhezion Biomedical in 2023.
H.B. Fuller is the largest pureplay adhesives company in the world. The company is based in St. Paul, Minnesota and is publicly traded on the New York Stock Exchange under the ticker symbol FUL.
